FDA Panel Recommends Keeping COVID Shots Targeted to Same Strain as Last Year

Corona New Variant JN.1 is spreading rapidly in many countries including India, know how dangerous this virus is

FDA gives Covid vaccine manufacturers instructions for next fall’s shot

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to update their vaccines.

FDA panel recommends keeping COVID shots targeted to same strain as last year

The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their booster doses to the “JN.1” coronavirus lineage.

Uncertainty loomed as FDA advisors met to discuss this year’s COVID shot - WorldNL Magazine

Calling it a "practical question," he asked, "If we were to change strains, can we assume that age-specific licensure won't change for any of these [vaccine] products?" Currently, COVID-19 boosters are accessible to those aged 6 months and up. Weir reiterated that there was no answer. Another FDA official, David Kaslow, chimed in to say only, "Rest assured that we're engaging with the manufacturers on this topic." As a follow-up to that exchange…

FDA VRBPAC Makes Recommendations For 2025-2026 Formula for COVID-19 Vaccines

The FDA committee advisors are recommending the monovalent JN1-lineage-based COVID-19 vaccines preferentially using the LP81 strain.

Uncertainty loomed as FDA advisors met to discuss this year’s COVID shot

(Ars Technica) – Expert advisors for the Food and Drug Administration met Thursday to discuss which virus strain this year’s updated COVID-19 vaccines should target. The advisors have been meeting around this time each year for such a strain selection, a routine decision in the process of updating the life-saving vaccines. (Read More)